Clinical Trial Update: Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC in AIS-A Level of Sub-acute SCI [Phase 1, Phase 2]

View source ↗

Summary

This ClinicalTrials.gov update describes a phase 1/2 study evaluating the safety and exploratory efficacy of transplanting PSA-NCAM(+) neural progenitor cells f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury

Drugs mentioned

• PSA-NCAM(+) Neural Progenitor Cell transplantation (PSA-NCAM positive neural progenitor cells)

Snippet

Sponsor: S.Biomedics Co., Ltd. | Conditions: Spinal Cord Injury, Acute, Spinal Cord Injury at C4 Level With Complete Lesion | Phase 1, Phase 2 | Status: RECRUITING